Patient Voice Missing In Asthma Drug Safety Debate – FDA’s Jenkins
Executive Summary
When a post-marketing safety signal arises, patients’ perspective of benefit is often drowned out by consumer advocates’ worries about a drug’s risks, the Office of New Drugs director says.
You may also be interested in...
Death Vs. Symptomatic Relief – Weighing Risks And Benefits For Asthma Drugs
When discussing a drug's benefits and risks, there is more to the equation than just death, Judith Kramer, Duke University, pointed out during a meeting of three FDA advisory committees to discuss asthma indications for long-acting beta agonists
FDA Panels Favor Advair, Symbicort Over Single-Entity LABAs For Asthma
Three FDA advisory committees recommended the withdrawal of asthma indications for two long-acting beta agonists - GlaxoSmithKline's Serevent (salmeterol) and Novartis's Foradil (formoterol) -during a Dec. 11 meeting
BrainStorm’s Phase III Data Do Not Support Clinical Benefit Of NurOwn In ALS, US FDA Says
Agency’s unusual public statement about an investigational product's development status may be aimed at countering bullish comments from the sponsor; FDA cites failure of pivotal trial on the primary and secondary endpoints and ‘modest excess in deaths’ with the cell therapy.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: